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Introduction {#sec1}
============

Since its discovery in 2012, Middle East Respiratory Syndrome Coronavirus (MERS-CoV) has infected over 2,000 people and has a mortality rate of approximately 35% ([@bib33]WHO; [@bib37]). The ancestral host species of MERS-CoV remains elusive; however, mounting evidence suggests that the virus most likely originated in bats and passed to humans through multiple zoonotic spill-over events from dromedary camels ([@bib4], [@bib15], [@bib16], [@bib34]). While species capable of supporting MERS-CoV infection have been studied, the genetic mechanisms underlying cross-species adaptation remain poorly understood.

A primary determinant of viral species-tropism is at the level of host cell entry, which is mediated by MERS-CoV spike protein binding host dipeptidyl peptidase 4 (DPP4) ([@bib22], [@bib25]). Structural studies have shown that this interaction relies on multiple contact points ([@bib19], [@bib28], [@bib32]). Our group has previously demonstrated that hamster DPP4 contains variation in these contact points, which prevents MERS-CoV replication ([@bib30], [@bib31]). Other genetic variation responsible for the glycosylation of DPP4 in mice, hamsters, ferrets, and guinea pigs forms an additional block to the interaction with MERS-CoV spike ([@bib9], [@bib24]). In contrast to small rodents and ferrets, MERS-CoV is capable of utilizing DPP4 from different bat species, and *Artibeus jamaicensis* bats have been shown to support experimental infection ([@bib8], [@bib21]).

Here, we investigated the host breadth and adaptability of MERS-CoV. We demonstrate that MERS-CoV can use DPP4 from a diverse range of bat species and can rapidly adapt to variation in DPP4.

Results {#sec2}
=======

Identification of a Semi-Permissive DPP4 Variant {#sec2.1}
------------------------------------------------

We selected 16 bat species representing a broad taxonomic and geographic distribution to screen for MERS-CoV entry ([Figures 1](#fig1){ref-type="fig"} A, [S1](#mmc1){ref-type="supplementary-material"}, and [S2](#mmc1){ref-type="supplementary-material"}). Plasmids encoding the bat DPP4s were transfected into Baby Hamster Kidney fibroblasts (BHK) cells, which are non-permissive to MERS-CoV infection ([@bib30]). All DPP4s supported viral replication to varying degrees; however, *Desmodus rotundus* DPP4 (*dr*DPP4) was the least permissive to viral replication ([Figure 1](#fig1){ref-type="fig"}B). Flow cytometry showed that DPP4 surface expression varied between species but did not correlate with infectivity ([Figure S3](#mmc1){ref-type="supplementary-material"}A). While this may result from variation in antibody recognition, to date, no commercially available DPP4 antibody recognizes an epitope that is conserved across all species.Figure 1*Desmodus Rotundus* DPP4 Is Semi-Permissive for MERS-CoV Replication(A) Phylogenetic tree of the DPP4 amino acid sequences used in this study. See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.(B) BHK cells were transfected with equivalent amounts of bat-DPP4 expression plasmids. Cells were infected 24 hr later with MERS-CoV at MOI = 1. Viral titer of 48-hr supernatants was determined by titration on Vero cells. Each dot on the graph represents one replicate and horizontal black lines represent the mean of three replicates. See also [Figure S3](#mmc1){ref-type="supplementary-material"}A.(C) Comparison of MERS-spike binding residues between human and *Desmodus rotundus* DPP4. See also [Figure S3](#mmc1){ref-type="supplementary-material"}B.(D) Structure of MERS-CoV spike protein bound to human DPP4 (PDB: [4L72](pdb:4L72){#intref0035}) with DPP4 residues 295 and 317 indicated in yellow and red, respectively.(E) Human and *dr*DPP4-295 and 317 mutants were transfected in BHK cells. Cells were infected 24 hr later with MERS-CoV at MOI = 1. Viral titer of 48-hr supernatants was determined by titration on Vero cells. Each dot on the graph represents one replicate, and horizontal black lines represent the mean of three replicates.

Relative to human DPP4, the bat DPP4s contained variation throughout the whole spike-binding region ([Figure S3](#mmc1){ref-type="supplementary-material"}B). However, within the residues, which specifically bind MERS-CoV spike, *dr*DPP4 only differed from human DPP4 in two amino acids at positions 295 and 317 ([Figures 1](#fig1){ref-type="fig"}C, 1D, and [S3](#mmc1){ref-type="supplementary-material"}B) ([@bib32]). As *dr*DPP4 was also unique at position 317 (R317Q), we chose to focus on *dr*DPP4. Introducing *dr*DPP4 mutations into human DPP4 reduced viral replication, while mutating *dr*DPP4 to match the amino acids in human DPP4 increased its ability to support MERS-CoV replication ([Figure 1](#fig1){ref-type="fig"}E). These data show that residues 295 and 317 largely determine resistance of *dr*DPP4 to MERS-CoV replication.

Viral Adaptation of MERS-CoV to *Desmodus Rotundus* DPP4 {#sec2.2}
--------------------------------------------------------

As only two *dr*DPP4 residues influenced MERS-CoV replication, we hypothesized that viral spike may be able to adapt to this variation. To test this, we generated BHK cell lines that stably expressed human DPP4, *dr*DPP4, or blue fluorescent protein (BFP; a negative control) from a lentiviral expression cassette that also included a fluorescent reporter, mCherry, as well as a puromycin selection gene ([Figure 2](#fig2){ref-type="fig"} A). These genes were separated by 2A sequences, which allowed for all three to express under the human Ef1α promoter ([@bib17]). Flow cytometry for mCherry and DPP4 confirmed similar transduction efficiency and transgene expression levels, respectively, between human and *dr*DPP4 cell lines ([Figure 2](#fig2){ref-type="fig"}B). Cells expressing *dr*DPP4 were less susceptible than human DPP4 to MERS-CoV infection, similar to our transfection experiments ([Figure 2](#fig2){ref-type="fig"}C).Figure 2Forced Adaptation of MERS-CoV on DPP4 Stable Cell Lines(A) An overview of the lentiviral expression cassette.(B) Flow cytometry of transduced cells.(C) Transduced cells were infected with MERS-CoV at MOI = 0.001. Viral titer was determined by titration on Vero cells. Error bars represent the SDs of three replicates.(D) MERS-CoV was passaged on DPP4-tansduced cells. Cytopathic effects were observed by passage 8.(E) Sequencing chromatograms of MERS-CoV spike from different passages on the *dr*DPP4 cells. Arrows indicate emerging mutations (overlapping peaks).(F) Schematic of single and double mutation emergence in MERS-CoV spike over different passages. See also [Figure S4](#mmc1){ref-type="supplementary-material"}A.(G) Location of mutations within MERS-CoV spike.(H) Location of mutations in the MERS-CoV spike co-structure with human DPP4 (PDB: [4L72](pdb:4L72){#intref0040}). MERS-CoV spike is colored blue and residues 465 and 510 are shown in pink and orange, respectively. DPP4 is colored gray and residues 295 and 317 are shown in yellow and red, respectively.

Wild-type (WT) MERS-CoV was serially passaged, in triplicate, on these DPP4 and control cell lines. While human DPP4 cells showed cytopathic effects (CPE) from the first passage, *dr*DPP4 cells only showed CPE after eight passages, indicative of viral adaptation ([Figure 2](#fig2){ref-type="fig"}D). Sanger sequencing of the MERS-CoV spike receptor binding domain (RBD) revealed the emergence of several mutations with the *dr*DPP4 cell cultures ([Figure 2](#fig2){ref-type="fig"}E). By the fifth passage, spike S465F emerged in two replicates, and spike D510H emerged in one replicate ([Figure 2](#fig2){ref-type="fig"}F). By passage 8, one S465F mutant acquired a secondary D510G mutation, and on passage 12, the D510H mutant acquired a secondary S465F mutation ([Figure 2](#fig2){ref-type="fig"}F). We sequenced the spike RBD from 14 passages, as well as full-length spike from passages 3, 6, and 9, but did not observe additional mutations. No spike mutations were observed with the human DPP4 or control cell lines, indicating that these mutations were specific for *dr*DPP4 and not the BHK cells themselves. Spike residues 465 and 510 are located within the RBD and interface with DPP4 ([Figures 2](#fig2){ref-type="fig"}G and 2H). Notably, spike residue 510 clusters with DPP4 residues 295 and 317 and directly interacts with DPP4 residue 317 ([Figure 2](#fig2){ref-type="fig"}H) ([@bib32]). MERS spike 465S and 510D are found in the majority of published spike sequences ([Figure S4](#mmc1){ref-type="supplementary-material"}A).

Characterization of MERS-CoV Spike Mutations {#sec2.3}
--------------------------------------------

Human and *dr*DPP4 are 83.8% similar at the amino acid level and both function as the receptor for MERS-CoV, suggesting the two proteins share a common structure. Therefore, we used structural data for human DPP4 to predict the structure of *dr*DPP4. Electrostatic potential analysis showed a positive surface charge of human DPP4 at residues 295 and 317 and a negative charge at these positions in *dr*DPP4 ([Figure 3](#fig3){ref-type="fig"} A). Complementary to human DPP4, the WT MERS-CoV spike RBD is negatively charged ([Figure 3](#fig3){ref-type="fig"}B). This analysis revealed that the spike adaptations altered the surface charge of spike from negative to positive, complementing the negative charge of *dr*DPP4 ([Figure 3](#fig3){ref-type="fig"}C).Figure 3Structural Analysis and Functional Testing of Spike Mutations(A) Surface charge of human DPP4 (amino acids 39--766; PDB: [4L72](pdb:4L72){#intref0045}) and predicted *dr*DPP4 structure (amino acids 37--765). Residues 295 and 317 are shown. Blue indicates positive charge, red indicates negative charge.(B) Surface charge of the MERS-CoV spike (amino acids 382--585; PDB: [4L72](pdb:4L72){#intref0050}).(C) Surface charge of MERS-CoV spike mutations.(D) DPP4 cells were infected with mutant viruses at MOI = 0.001 and supernatants were collected at the indicated time points. Viral titer was determined qRT-PCR. Error bars represent the SDs of three replicates. See also [Figure S4](#mmc1){ref-type="supplementary-material"}B.(E) DPP4 transduced cells were infected with spike-pseudotyped VSV-particles and luciferase was measured 24 hr later. Error bars represent the SDs of three replicates.

Because we only sequenced MERS-CoV spike, it remained possible that other mutations arose in the viral genome that increased viral replication in the *dr*DPP4 cells. Therefore, we generated spike point mutant viruses, which failed to grow on control transduced cells but grew to similar levels as WT virus and induced CPE in the human DPP4 cells ([Figures 3](#fig3){ref-type="fig"}D and S4B). In contrast, WT virus replicated to lower titers than the spike mutants and failed to induce CPE in *dr*DPP4 cells ([Figures 3](#fig3){ref-type="fig"}D and [S4](#mmc1){ref-type="supplementary-material"}B). Next, we performed an entry assay with spike-pseudotyped vesicular stomatitis virus (VSV) particles expressing luciferase. While all spike mutations slightly increased entry over WT spike on human DPP4 cells, there was a striking increase in entry with *dr*DPP4 cells ([Figure 3](#fig3){ref-type="fig"}E). Collectively, these findings demonstrate that adaptation in MERS-CoV spike enhanced viral replication on *dr*DPP4 cells through increased viral entry.

Spike Adaptation Specificity {#sec2.4}
----------------------------

We transfected cells with a subset of the bat DPP4 panel and then infected with spike mutant viruses, all of which replicated better than WT virus on cells expressing *dr*DPP4 ([Figure 4](#fig4){ref-type="fig"} ). While some mutants performed better than WT virus on cells expressing other bat DPP4s, there was not a consistent top-performing mutant. Notably, spike-510H only replicated better than WT virus with *dr*DPP4 and not the other bat DPP4s, suggesting that this mutation is specific for *dr*DPP4.Figure 4Spike Adaptation SpecificityBHKs were transfected with indicated DPP4s and infected with mutant viruses at MOI = 0.005. Viral titer of supernatants taken at 72 hr was determined by qRT-PCR. Error bars represent SDs of two replicates.

Discussion {#sec3}
==========

While numerous studies have shown that MERS-CoV can infect several different species, our understanding of the genetic mechanisms underlying cross species spillover remains unclear ([@bib1], [@bib2], [@bib10], [@bib12], [@bib14], [@bib21]). Here, we investigated species promiscuity and adaptability of MERS-CoV.

Previous studies have shown that MERS-CoV entry is less efficient with DPP4 from pipistrelle bats compared to human DPP4 ([@bib7], [@bib25], [@bib36]). This difference in receptor efficiency was used to suggest that MERS-CoV spike adapted away from using bat DPP4 as it adapted to human DPP4. While our data confirm this replication phenotype with *Pipistrellus* DPP4, we showed that DPP4 from several other bat species supported MERS-CoV replication comparable to or better than human DPP4 ([Figure 1](#fig1){ref-type="fig"}B). Thus, without more evidence as to the true ancestral host of MERS-CoV, conclusions regarding spike adaptation away from bats should be more reserved. This finding also highlights the importance of screening a broad selection of species when assessing host breadth.

*A. planirostris* and *A. jamaicensis* DPP4s are identical to human DPP4 at the 14 contact points with spike but differed in their ability to support MERS-CoV replication ([Figure 1](#fig1){ref-type="fig"}B). Notably, these two bat DPP4 sequences varied from human DPP4 and from each other at other positions in the receptor binding domain ([Figure S3](#mmc1){ref-type="supplementary-material"}B), suggesting that additional DPP4 residues can influence the interaction with spike.

Forced adaptation of MERS-CoV spike has been a challenge in the field as DPP4 from most non-permissive species contains glycosylation that completely abrogates the interaction and blocks infection ([@bib9], [@bib23], [@bib24]). Without viral replication, it has not been possible to experimentally demonstrate evolution of the MERS-CoV spike. We found that *dr*DPP4 was only semi-permissive to viral infection and, therefore, served as a tool to test MERS-CoV spike adaptation *in vitro* ([Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). Within three passages on cells expressing *dr*DPP4, MERS-CoV accumulated mutations in the receptor-binding domain of spike that enhanced viral entry and replication specifically with *dr*DPP4 and not the other bat DPP4s ([Figures 2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}, and [4](#fig4){ref-type="fig"}). The prevalence of these adaptation mutations is low in published sequences, further suggesting that they are specific for *dr*DPP4 ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Taken together, MERS-CoV spike is likely adaptable to any DPP4 variation that does not completely ablate the interaction.

At least 14 contact points have been identified in crystal structures of human DPP4 and MERS-CoV spike ([@bib32]). *dr*DPP4 contains variation within and around these known points ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Therefore, the spike-465F mutation, which is just outside of the interface, may lead to broader structural adjustments that favor interaction with *dr*DPP4 ([Figure 2](#fig2){ref-type="fig"}H). Surprisingly, the adaptation mutations had very little effect on the interaction with human DPP4, suggesting that other contact points could compensate for this variation ([Figure 3](#fig3){ref-type="fig"}). For example, spike residue 510 has been shown to contact DPP4 residue 322 in addition to 317, so it may be possible that this interaction is retained with human DPP4 ([@bib32]). Structural studies are needed to fully define how these spike mutations influence the interface with DPP4.

Our viral adaptation experiments revealed mutations in MERS-CoV spike, which altered the surface charge to complement the opposite charge of *dr*DPP4 ([Figure 3](#fig3){ref-type="fig"}C). Interestingly, these mutations share a striking similarity to species adaptations identified in SARS-CoV spike (as reviewed in [@bib18]). The ability to rapidly adjust surface charge may be a general property of MERS-CoV spike to facilitate cross-species adaptation. However, animal studies are needed to see if the mutations we described here affect other viral phenotypes, including host immune evasion.

Previous work has assessed coronavirus spike adaptation to orthologous host receptors ([@bib6], [@bib20], [@bib26], [@bib27], [@bib35]). These studies characterized viruses after passage in animals, long-term cell culture, or performed biochemical analysis on spike variations from different isolates. As these experiments only focused on the viral endpoint, they failed to capture the continuous evolution through viral passages. Thus, the exact speed and order in which mutations arise in response to receptors from non-cognate species remain unclear in these studies. The work we present here demonstrates that MERS-CoV rapidly adapts to DPP4 variation and can do so utilizing different mutation paths. While *D. rotundus* is not known to be a host species for MERS-CoV, the use of its semi-permissive DPP4 allowed us to observe, with high temporal resolution, species adaptation of MERS-CoV. All together, these findings shed light on the evolutionary mechanisms underlying MERS-CoV cross-species transmission.

Experimental Procedures {#sec4}
=======================

Biosafety Statement {#sec4.1}
-------------------

All work with infectious MERS-CoV was approved by the Rocky Mountain Laboratories Institutional Biosafety Committee and performed under biosafety level 3 conditions.

Sequencing of Bat DPP4 {#sec4.2}
----------------------

cDNA from *E. buettikoferi* and *R. aegyptiacus* were derived from the EpoNi/22.1 and RE06 cell lines, respectively. cDNA was produced from *A. planirostris*, *C. perspicillata*, and *S. bilineata* primary lung tissue and *H. gigas* heart tissue, provided by Dr. Tony Schountz. Dr. Lin-Fa Wang provided cDNA extracted from *R. ferrumequinum* primary kidney tissue. DPP4 was amplified using the iProof High-fidelity PCR kit (Bio-Rad), following the manufacturer's instructions and Sanger sequencing.

Plasmids {#sec4.3}
--------

DPP4 coding sequences from human (NM001935.3), *A. jamaicensis* (KF574262), *A. planirostris* (MH299895), *C. perspicillata* (MH299896), *D. rotundus* (GABZ01004546.1), *E. buettikoferi* (MH299897), *E. fuscus* (XM008138769), *H. gigas* (MH299898), *M. brandtii* (XM005859372.1), *M.davidii* (XM006766490.1), *M. lucifugus* (XM006083213.1), *P. pipistrellus* (KC249974.1), *P. alecto* (XM006921123.1), *P. vampyrus* (XM011358549), *R. ferrumequinum* (MH299899), *R. aegyptiacus* (MH299900), and *S. bilineata* (MH299901) were synthesized into pcDNA3.1 (Thermo-Fisher). DPP4 was cloned into the lentiviral expression vector provided by Dr. Viviana Simon. MERS-CoV spike plasmid was provided by Dr. Fang Li. Mutations were introduced into DPP4, pBAC-MERS/EMC12, or the MERS-spike plasmid by overlap PCR.

Viruses {#sec4.4}
-------

MERS-CoV/EMC12 was propagated as previously described ([@bib31]). The WT virus stock was deep sequenced on the Illumina platform to confirm the absence of mutations described in this study. Mutant viruses were rescued as previously described ([@bib3]). Titers of all viruses used in this study were determined by endpoint titration in Vero cells as previously described ([@bib30]).

Transfections {#sec4.5}
-------------

Cells were transfected, in 6-well format, with 3 μg of DNA using Lipofectamine 2000 (Life Technologies), following the manufacturer's instructions.

Lentiviral Vectors, Cell Transduction, and Flow Cytometry {#sec4.6}
---------------------------------------------------------

Lentiviral particles were produced in 293T cells. Transduced BHKs were placed under 1 μg/mL puromycin selection, as described previously ([@bib17]). Flow cytometry was used to determine mCherry transduction efficiency and DPP4 expression (AF1180, R&D Systems).

Forced Adaptation of MERS-CoV EMC 2012 on Transduced Cells {#sec4.7}
----------------------------------------------------------

Human DPP4, *dr*DPP4, and BFP cells were infected with MERS-CoV/EMC12 at an MOI of 0.01 in triplicate. Every 72 hr, 250 μL of supernatant from each replicate was transferred to fresh cell cultures. For each passage, RNA was extracted from supernatant using the QIAamp Viral RNA kit (QIAGEN) and converted to cDNA using SuperScript III (Invitrogen). The spike RBD was amplified and Sanger sequenced. Full-length spike was sequenced for passages 3, 6, and 9.

Structural Modeling and Electrostatic Potential Analysis {#sec4.8}
--------------------------------------------------------

The co-structure of MERS-CoV spike and human DPP4 (PDB ID: [4L72](pdb:4L72){#intref0010} \[[@bib32]\]) was modeled in Pymol and used to predict the structure for *dr*DPP4 (<https://swissmodel.expasy.org>). Poisson-Boltzmann analysis was performed with the PDB2PQR server ([@bib13]) and adaptive Poisson-Blotzmann Solver tool extension in Pymol ([@bib5]).

MERS-CoV Replication Kinetics {#sec4.9}
-----------------------------

Viral RNA was extracted from culture supernatants with the QIAamp viral RNA kit (QIAGEN). MERS-CoV titer of cell culture supernatants was determined by endpoint titration on Vero cells ([@bib31]) or qRT-PCR as previously described ([@bib11]).

Pseudotype Entry Assay {#sec4.10}
----------------------

Pseudotyped VSV particles were produced as previously described and titered on Vero cells ([@bib29]). BHK-DPP4 cells were infected at an MOI = 1 with pseudotyped particles as previously described ([@bib36]). Luciferase was measured 24 hr post-infection using a firefly luciferase detection kit (Promega) and a Synergy HTX plate reader (Biotek).

Statistical Methods {#sec4.11}
-------------------

GraphPad (Prism) was used to analyze quantitative viral titer and viral entry data.

Data and Software Availability {#app1}
==============================

Accession numbers for the novel DPP4 sequences reported in this paper are GenBank: MH299895-MH299901. DPP4 sequence alignment from this study is available via Mendeley Data: <https://data.mendeley.com/datasets/232nv29t87/1>.
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